Sichuan Kelun-Biotech Biopharmaceutical Future Growth
Future criteria checks 5/6
Sichuan Kelun-Biotech Biopharmaceutical is forecast to grow earnings and revenue by 3.9% and 24.2% per annum respectively. EPS is expected to grow by 6.4% per annum. Return on equity is forecast to be -1.2% in 3 years.
Key information
3.9%
Earnings growth rate
6.4%
EPS growth rate
Biotechs earnings growth | 42.6% |
Revenue growth rate | 24.2% |
Future return on equity | -1.2% |
Analyst coverage | Good |
Last updated | 14 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,574 | -211 | -122 | 57 | 16 |
12/31/2025 | 1,644 | -646 | -496 | -392 | 16 |
12/31/2024 | 1,818 | -269 | -473 | -518 | 16 |
6/30/2024 | 1,877 | -187 | -567 | -480 | N/A |
3/31/2024 | 1,709 | -354 | -295 | -210 | N/A |
12/31/2023 | 1,540 | -522 | -23 | 60 | N/A |
9/30/2023 | 1,523 | -427 | 135 | 207 | N/A |
6/30/2023 | 1,505 | -333 | 292 | 355 | N/A |
3/31/2023 | 1,155 | -440 | -9 | 42 | N/A |
12/31/2022 | 804 | -548 | -310 | -271 | N/A |
12/31/2021 | 32 | -823 | -581 | -486 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6990 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: 6990 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 6990 is expected to become profitable in the next 3 years.
Revenue vs Market: 6990's revenue (24.2% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 6990's revenue (24.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6990 is forecast to be unprofitable in 3 years.